Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer

Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer Publisher Pubmed

Mikaeili A¹ ; Erfani M² ; Shafiei M² ; Kobarfard F³ ; Abdi K¹ ; Sabzevari O⁴

Show Affiliations

1. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 14395-836, Tehran, 1439951113, Iran
3. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, P.O. Box: 14155-6451, Tehran, 1417614411, Iran

Source: Cancer Biotherapy and Radiopharmaceuticals Published:2018

Abstract

Due to high expression of CXCR4 (CXC chemokine receptor type 4) receptors in many tumors and metastasis, synthesis and labeling of CXCR4 receptor-targeted analogs as tumor imaging agents have been encouraged. Herein, CXCR4 receptor-targeted peptide antagonist was prepared and thereafter its labeling with 99mTc by a bifunctional chelating agent and tricine coligand was developed. Radiotracer purity, stability, and tumor cell binding were assessed. Bioevaluation of radiotracer was performed in mice bearing xenograft tumor. More than 95% labeling yield and stability up to 24 hours were observed. Radiotracer-related tumor accumulation was 3.61 ± 0.15% ID/g at 1 hour postinjection. High stability and specific tumor uptake are important characteristics of the radiotracer that could nominate this as a targeted imaging agent in the future. © Copyright 2018, Mary Ann Liebert, Inc.

Related Docs

View other Related Docs

1. Synthesis and Evaluation of a 99Mtc-Labeled Chemokine Receptor Antagonist Peptide for Imaging of Chemokine Receptor Expressing Tumors, Nuclear Medicine and Biology (2017)

2. Design of a New 99M99mtc-Radiolabeled Cyclo-Peptide As Promising Molecular Imaging Agent of Cxcr4 Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation, Current Radiopharmaceuticals (2024)

3. Application of Radiolabeled Peptides in Tumor Imaging and Therapy, Life Sciences (2020)

4. The Role of Cxc Chemokines and Receptors in Breast Cancer, Clinical and Experimental Medicine (2025)

5. Breast Tumor Targeting in Mice Bearing 4T1 Tumor With Labeled Cxcr4 Antagonist Analogue, International Journal of Peptide Research and Therapeutics (2021)

6. Preparation and Preliminary Biological Evaluation of [153Sm] Samarium Amd3100; Towards a Possible Therapeutic Chemokine Receptor Cxcr4 Targeting Complex, Iranian Journal of Nuclear Medicine (2015)

7. A99mtc-Tricine-Hynic-Labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging, Iranian Journal of Pharmaceutical Research (2016)

8. Pathogenesis of Breast Cancer Metastasis to Brain: A Comprehensive Approach to the Signaling Network, Molecular Neurobiology (2016)

Experts (# of related papers)

View all Related Experts

Omid Sabzevari (3)

Davood Beiki (2)

Style	Citing Format
MLA	Mikaeili A, et al.. "Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer." Cancer Biotherapy and Radiopharmaceuticals, vol. 33, no. 1, 2018, pp. 17-24.
APA	Mikaeili A, Erfani M, Shafiei M, Kobarfard F, Abdi K, Sabzevari O (2018). Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer. Cancer Biotherapy and Radiopharmaceuticals, 33(1), 17-24.
Chicago	Mikaeili A, Erfani M, Shafiei M, Kobarfard F, Abdi K, Sabzevari O. "Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer." Cancer Biotherapy and Radiopharmaceuticals 33, no. 1 (2018): 17-24.
Harvard	Mikaeili A et al. (2018) 'Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer', Cancer Biotherapy and Radiopharmaceuticals, 33(1), pp. 17-24.
Vancouver	Mikaeili A, Erfani M, Shafiei M, Kobarfard F, Abdi K, Sabzevari O. Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer. Cancer Biotherapy and Radiopharmaceuticals. 2018;33(1):17-24.
BibTex	@article{ author = {Mikaeili A and Erfani M and Shafiei M and Kobarfard F and Abdi K and Sabzevari O}, title = {Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer}, journal = {Cancer Biotherapy and Radiopharmaceuticals}, volume = {33}, number = {1}, pages = {17-24}, year = {2018} }
RIS	TY - JOUR AU - Mikaeili A AU - Erfani M AU - Shafiei M AU - Kobarfard F AU - Abdi K AU - Sabzevari O TI - Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer JO - Cancer Biotherapy and Radiopharmaceuticals VL - 33 IS - 1 SP - 17 EP - 24 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract